Multicenter follow-up study of a new artificial hip joint in which 2-methacryloyloxyethyl phosphorylcholine polymer is grafted onto the bearing surface of highly cross-linked ultrahigh molecular weight polyethylene liner

Multicenter follow-up study of a new artificial hip joint in which 2-methacryloyloxyethyl phosphorylcholine polymer is grafted onto the bearing surface of highly cross-linked ultrahigh molecular weight polyethylene liner - Multicenter follow-up study of a new artificial hip joint in which MPC polymer is grafted onto the bearing surface of highly cross-linked UHMWPE liner

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003681

Enrollment

Registered

2010-05-31

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hip joint disease caused by hip osteoarthritis and others.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hip joint disease, who participated in the previous clinical trial using the investigational device, JMM-H01, and consented to this study in written form.

Exclusion criteria

Exclusion criteria: 1) Patients whose JMM-H01 has been retrieved 2) Patients whom the investigator(s) judged not necessary for further investigation due to worsening of complications. 3) Patients whom the investigator(s) judged not necessary for further investigation due to inappropriateness to participate to this study.

Design outcomes

Primary

Measure	Time frame
Efficacy 1) Survival rate of the investigational device, JMM-H01 2) Radiographic assessment 3) Clinical evaluation -Evaluation chart of hip joint function (Japanese Orthopaedic Association, 1995) -Merle d'Aubigne-Postel score -QOL assessment (SF-36) Safety 1) Adverse events	—

Countries

Japan

Contacts

Public ContactKiyoyasu Fujii

KYOCERA Medical Corporation Regulatory Affairs Development Dept. Research and Development Corporate Division

kiyoyasu.fujii@kyocera-md.jp06-6350-1493

Outcome results